Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
DENTSPLY SIRONA Inc Market Cap
The DENTSPLY SIRONA Inc (XRAY) share price is expected to increase by 23.9% over the next year. This is based on calculating the average 12-month share price estimate provided by 15 stock analysts who have covered XRAY. Price targets range from $19 at the low end to $35 at the high end. The current analyst consensus for XRAY is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
DENTSPLY SIRONA Inc has a total of 15 Wall St Analyst ratings. There are 8 buy ratings, 7 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that DENTSPLY SIRONA Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of XRAY.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jeffrey Johnson Baird | Neutral | $24 | Maintains | Nov 8, 2024 |
| Michael Petusky Barrington Research | Outperform | $24 | Maintains | Nov 8, 2024 |
| Michael Cherny Leerink Partners | Market Perform | Downgrade | Nov 7, 2024 | |
| David Saxon Needham | Buy | $29 | Maintains | Oct 28, 2024 |
| Elizabeth Anderson Evercore ISI Group | Outperform | $27 | Maintains | Oct 8, 2024 |
| Michael Petusky Barrington Research | Outperform | $36 | Maintains | Sep 20, 2024 |
| David Saxon Needham | Buy | $34 | Reiterates | Aug 20, 2024 |
| David Saxon Needham | Buy | $34 | Maintains | Jul 31, 2024 |
| Jeffrey Johnson Baird | Neutral | $31 | Maintains | Jul 22, 2024 |
| Jonathan Block Stifel | Hold | $28 | Maintains | Jul 18, 2024 |
| Elizabeth Anderson Evercore ISI Group | Outperform | $27 | Maintains | Jul 9, 2024 |
| Michael Petusky Barrington Research | Outperform | $38 | Maintains | Jul 8, 2024 |
| Elizabeth Anderson Evercore ISI Group | Outperform | $28 | Maintains | Jun 25, 2024 |
| Nathan Rich Goldman Sachs | Neutral | $30 | Maintains | May 6, 2024 |
| Elizabeth Anderson Evercore ISI Group | Outperform | $35 | Maintains | May 3, 2024 |
| David Saxon Needham | Buy | $36 | Maintains | May 3, 2024 |
| Jeffrey Johnson Baird | Neutral | $33 | Maintains | May 3, 2024 |
| Jason Bednar Piper Sandler | Neutral | $32 | Reiterates | May 3, 2024 |
| Michael Petusky Barrington Research | Outperform | $38 | Maintains | May 3, 2024 |
| Michael Petusky Barrington Research | Outperform | $41 | Maintains | Apr 18, 2024 |
When did it IPO
1991
Staff Count
15,000
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Simon D. Campion
Market Cap
$3.91B
In 2023, XRAY generated $3.97B in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that XRAY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 27 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - A class action lawsuit has been filed against DENTSPLY SIRONA Inc. (NASDAQ: XRAY). Investors can contact Pomerantz LLP for more information.
Why It Matters - A class action lawsuit against Dentsply SIRONA Inc. could lead to financial liabilities or reputational damage, impacting stock performance and investor sentiment.
Wed, 27 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - A class action lawsuit has been filed against Dentsply Sirona Inc. for alleged federal securities law violations, affecting investors who purchased securities from Dec 1, 2022, to Nov 6, 2024.
Why It Matters - The class action lawsuit against Dentsply Sirona Inc. signals potential legal and financial risks, which could impact stock performance and investor sentiment.
Thu, 28 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - A class action lawsuit has been filed against Dentsply Sirona Inc. (NASDAQ: XRAY) for alleged federal securities law violations affecting investors from December 1, 2022, to November 6, 2024.
Why It Matters - A class action lawsuit against Dentsply Sirona Inc. suggests potential financial liabilities and regulatory risks, which could negatively impact stock performance and investor confidence.
Thu, 28 Nov 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - A lawsuit has been filed against Dentsply Sirona Inc. (NASDAQ: XRAY) and its executives for potential federal securities law violations. Investors can find more information at Bleichmar Fonti & Auld LLP's website.
Why It Matters - A lawsuit against Dentsply Sirona Inc. for potential securities law violations could lead to legal liabilities and financial penalties, impacting the company's stock performance and investor confidence.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - A class action lawsuit has been filed against Dentsply Sirona Inc. for securities fraud, covering stock purchases from Dec 1, 2022, to Nov 6, 2024. The case is in the Southern District of New York.
Why It Matters - A securities fraud class action against Dentsply Sirona could lead to financial penalties and reputational damage, impacting the company's stock performance and investor confidence.
Thu, 28 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Rosen Law Firm has filed a class action lawsuit for Dentsply Sirona Inc. (NASDAQ: XRAY) stock purchasers from December 1, 2022, to November 6, 2024.
Why It Matters - The class action lawsuit against Dentsply Sirona may indicate potential legal and financial risks for the company, impacting stock performance and investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
